Latch launches Antibody Discovery Benchmark with 100 evaluations for AI agents
anshulkundaje · x · 2026-09-03
Latch introduced the Antibody Discovery Benchmark, testing whether AI agents can make scientific decisions across therapeutic antibody discovery stages.
- 100 evaluations across ten areas from real drug programs: target and modality selection, assay design, binder discovery, binding characterization, cellular pharmacology, antibody engineering, and preclinical candidates.
- Quality control: tasks are peer-reviewed by multiple scientists plus AI rubric checks; each is hard-but-solvable, confirmed by humans and at least one model; benchmarks take a team of 5+ scientists over a month to build.
- Stanford professor Anshul Kundaje notes public benchmarks are often biased, underscoring the need for careful data vetting.
Related event: LatchBio Releases Antibody Discovery Benchmark for AI Agents(5 posts)→
More from Research
- TRACE Open-Sourced: Migrating G1 Controller to Full-Size Humanoid H2 in 8 Hours on One GPU — zhengyiluo · 2026-10-18
- Humanoid Robot Funding Tops $3B as Brian Potter Explains the VLA Models Driving Robots — scottleibrand · 2026-10-18
- Terence Tao on 'War Footing' as OpenAI Claims Navier-Stokes Solve Shakes Mathematics — AlexTensor · 2026-10-18
- Univ. of Tokyo paper: why your recorded voice feels eerie — a vocal uncanny valley — ssh4net · 2026-10-18
- MIT's SANDO Drone Planner Avoids Every Moving Obstacle Across 12 Real Flights — Olivier__OG · 2026-10-18
- No-backprop pretraining speedup of 2.3x claimed, inspired by mech interp essay — CatAstro_Piyush · 2026-10-18